**FINANCES**

What resources were available to support the national program in the past six years? And what resources are available in the coming three years?

### Historical investments by funding source (2012-2017)

<table>
<thead>
<tr>
<th>Funding Source</th>
<th>2014-2016 Allocation period</th>
<th>2017-2019 Allocation period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria</td>
<td>$85.9m</td>
<td>$32.2m</td>
</tr>
<tr>
<td>RSSH</td>
<td>$6.76m</td>
<td></td>
</tr>
</tbody>
</table>

In 2015-2017, 90% of NSP need was funded.

**Malaria financing**

### Planned investments by funding source and intervention (2018-2020)

<table>
<thead>
<tr>
<th>Label</th>
<th>Total amount in budget: $218m</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Prevention $101m</td>
</tr>
<tr>
<td>B</td>
<td>Case management $81m</td>
</tr>
<tr>
<td>C</td>
<td>RSSH $28m</td>
</tr>
<tr>
<td>D</td>
<td>Program management $10m</td>
</tr>
</tbody>
</table>

*Domestic – funding request submitted to the Global Fund, External – country reported, OECD DAC CRS

### Global Fund Results (2017)

- **Nets distributed:**
  - 2012: 100%
  - 2013: 50%
  - 2014: 60%
  - 2015: 100%

- **Structures receiving IRS:**
  - 2012: 88%
  - 2013: 60%

**Malaria cases**

- 2017: 0% of estimated malaria cases were P. Vivax, 100% were P. Falciparum.

### Impact

**Change in malaria deaths:**
- 25% reduction from 2012 to 2017
- 42% reduction from 2000 to 2017

**Change in malaria cases:**
- 14% reduction from 2012 to 2017
- 12% increase from 2000 to 2017

### Notes

Detailed notes are available on the separate Explanatory Notes page.

1. Among those who received antimalarial drugs.

2. Calculations based on previous years' data or estimated figures.